Angiogenesis in gastric cancer: Hitting the target?

The Lancet

Volumn 383, Issue 9911, 2014, Pages 4-6

  Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEUROPILIN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLATINUM; PYRIMIDINE DERIVATIVE; RAMUCIRUMAB; TRASTUZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADVANCED CANCER; ANGIOGENESIS; BLINDNESS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL CANCER; DISEASE COURSE; DISEASES; DRUG TREATMENT FAILURE; ESOPHAGUS CANCER; HUMAN; METASTASIS; NOTE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; SYSTEMIC THERAPY; ADENOCARCINOMA; FEMALE; LOWER ESOPHAGUS SPHINCTER; MALE; STOMACH TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; STOMACH NEOPLASMS;

EID: 84892713518     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61892-9     Document Type: Note

References (16)

1. Sasako M, Sakuramoto S, Katai H, et al. Five year update of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-933.
2. Bang YK, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open label randomized controlled trial. Lancet 2012; 379: 315-21.
3. Cunningham D, Allum W, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
4. Macdonald J, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-97.
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced gastric cancer. N Engl J Med 2008; 358: 36-46.
7. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistiche Onkologie. J Clin Oncol 2008; 26: 1435-42.
8. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first line therapy in patients with advanced gastric cancer: a randomized phase III non inferiority trial. Ann Oncol 2009; 20: 666-73.
9. Koizumi W, Narahara H, Hara T, et al. S-1 cisplatin versus S-1 alone for firstline treatment of advanced gastric cancer (SPIRITS Trial): a phase III trial. Lancet Oncol 2008; 9: 215-21.
10. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer, a randomized double blind placebo controlled phase III trial. J Clin Oncol 2011; 29: 3968-76.
11. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated esophagogastric cancer (REAL-3): a randomized open label phase 3 trial. Lancet Oncol 2013; 14: 481-89.
12. Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized open label phase 3 trial. Lancet Oncol 2013; 14: 490-99.
13. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
14. Fuchs CS, Tomasek J, Yong CJ, et al, for the REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2013; published online Oct 3. http://dx.doi.org/10.1016/S0140-6736(13)61719-5.
15. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-27.
16. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res 2013; 19: 2824-27.